NCT05371808Recruiting
Economic Analysis of Early vs Delayed Therapy in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma:
An Economic Analysis of Early vs Delayed Therapy in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Companion Analysis to CCTG CLC.3/SWOG 1925 Randomized Phase III Clinical Trial
Source: ClinicalTrials.gov · Last updated 14 Oct 2026
Brief summary (registry, in English)
Utilization data will be collected from all patients entered on the trial at Canadian centres from the time of registration until death, removal from study, or completion of 10 years of follow-up. Protocol-specified health care utilization will be collected within trial case report forms, and will include study visits, radiographic assessments, laboratory investigations, and treatment administration. Resource utilization data collection will be supplemented by a self-administered resource utilization form (Stanford SMRC) to document non-protocol specified utilization. This will include hospitalizations (including days in hospital), emergency room visits, and non-protocol specified ambulatory visits.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 247 (estimated)
- First submitted
- 9 May 2022
- Start date
- 27 Jan 2023
- Primary completion date
- 1 Oct 2028
- Lead sponsor
- Canadian Cancer Trials Group
- Diseases
- Chronic lymphocytic leukaemia
- NCT number
- NCT05371808
What you commit to
- Study type: Observational
- Planned participants: 247
- From 27 Jan 2023 to the primary completion date, 1 Oct 2028
- 6 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Who the study is looking for
- Patient must be eligible for the core CLC3/S1925 protocol.
- Patient consent must be appropriately obtained in accordance with applicable local and regulatory requirements. Each patient must sign a consent form prior to enrollment in the trial to document their willingness to participate.
- Patient is able (i.e. sufficiently fluent) and willing to complete the quality of life and/or health utility questionnaires in either English or French. The baseline assessment must be completed within required timelines, prior to enrollment. Inability (lack of comprehension in English or French, or other equivalent reason such as cognitive issues or lack of competency) to complete the questionnaires will not make the patient ineligible for the study. However, ability but unwillingness to complete the questionnaires will make the patient ineligible.
- Patients must be accessible for treatment and follow-up. Investigators must assure themselves the patients enrolled on this trial will be available for complete documentation of the treatment, adverse events, and follow-up.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (6)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The Jewish General Hospital Coordinator of this site? Confirm its status | Montreal | Canada | Recruiting |
| Lakeridge Health Oshawa Coordinator of this site? Confirm its status | Oshawa | Canada | Not yet recruiting |
| Ottawa Hospital Research Institute Coordinator of this site? Confirm its status | Ottawa | Canada | Withdrawn |
| Regional Health Authority B, Zone 2 Coordinator of this site? Confirm its status | Saint John | Canada | Recruiting |
| BCCA - Vancouver Coordinator of this site? Confirm its status | Vancouver | Canada | Recruiting |
| CancerCare Manitoba Coordinator of this site? Confirm its status | Winnipeg | Canada | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.